Swedish Orphan Biovitrum Ab · OMXSTO:SOBI
Swedish Orphan Biovitrum Ab — Merger or Acquisition (September 2019)
15 slides from Swedish Orphan Biovitrum Ab's merger presentation, Sep 30, 2019
Slide 1: Sobi to acquire Dova Pharmaceuticals
Sobi to acquire Dova Pharmaceuticals Creating a global growth platform in haematology 30 September 2019
Slide 2: Forward looking statements
Forward looking statements In order to utilise the ‘Safe Harbor’ provisions of the United States Private Securities Litigation Reform Act of 1995, Swedish Orphan Biovitrum AB (publ) is providing the following cautionary statement. This presentation contains forward-looking statements with respect to
Slide 3: Presenters
Presenters CFO Guido Oelkers Henrik Stenqvist Milan Zdravkovic Chief Executive Officer & President Chief Financial Officer Head of R&D & Chief Medical Officer 3
Slide 4: Sobi is excited to add Doptelet to its haematology franchise
Sobi is excited to add Doptelet to its haematology franchise Deal terms • Single asset company with launch-phase asset • The transaction is valued at up to USD 915 million (approximately SEK 9.0 billion) on a fully diluted basis • Doptelet® (avatrombopag), orally administered, second generation thro
Slide 5: Fully aligned with our growth strategy
Fully aligned with our growth strategy Grow within Expand geographic Strengthen late- Haematology footprint stage pipeline Significant growth CLD and ITP launch in the Phase 3 trial in CIT, area opportunities with US underway; already with high unmet medical differentiated product approved in CLD in
Slide 6: Thrombocytopenia is a serious bleeding disorder
Thrombocytopenia is a serious bleeding disorder • Thrombocytopenia results in low levels of • Thrombocytopenia can be the result of a blood platelets causing bleeding related number of diseases that impairs production, symptoms causes increased rate of destruction, spleen sequestration and transfusi
Slide 7: Doptelet is a differentiated thrombopoietin (TPO) receptor agonist
Doptelet is a differentiated thrombopoietin (TPO) receptor agonist • Avatrombopag has demonstrated efficacy and is approved for thrombocytopenia in adults with: • Chronic liver disease (CLD) undergoing a Efficacy procedure (EU and US) • Chronic immune thrombocytopenia (ITP) who have had an insuffici
Slide 8: Doptelet will enhance Sobi’s haematology franchise
Doptelet will enhance Sobi’s haematology franchise • Doptelet (avatrombopag) is an orally administered, second generation thrombopoietin Expanding into receptor agonist (TPO-RA) serving an unmet medical need in patients with Haematology thrombocytopenia Established and • TPOs represent a large, esta
Slide 9: Fully integrated functions in the US
Fully integrated functions in the US North American team of 350, including: A team of 125, including: 250 field based medico-marketing organisation 60% of headcount field based medico-marketing supporting Synagis, Gamifant and Kineret organisation focused on haematology in the US An R&D team focused
Slide 10: Haematology will be a dynamically growing franchise in the years to come
Haematology will be a dynamically growing franchise in the years to come We have brought the first With TPO we expand into Doptelet will create a strong Sobi will bring another game innovation in 20 years in the haematology with cadence of launches across changer to Haemophilia market very conservat
Slide 11: Doptelet will contribute to growth in haematology with a series of launches
Doptelet will contribute to growth in haematology with a series of launches over the coming years 2019 2020 2021 2022 2023 BIVV 001 CLD ITP US CIT EU ROW 11
Slide 12: Transaction terms
Transaction terms • Dova shareholders to receive USD 27.50 per share in cash upfront Consideration • Additional payment of USD 1.50 per share contingent on CIT approval in the US • Values transaction at up to USD 915 million on a fully diluted basis • Expected to be accretive to EPS in 2022 and sign
Slide 13: Conclusion
Conclusion Build leadership in • Building a strong Haematology franchise on the strengths of our two haematology leading extended half-life products, Elocta and Alprolix Diversify and expand • Dova acquisition enables a cadence of launches of new indications in geographic footprint various geographi
Slide 14: Q&A
Q&A 14
Slide 15: Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
Sobi is a trademark of Swedish Orphan Biovitrum AB (publ). © 2019 Swedish Orphan Biovitrum AB (publ) – All rights reserved Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm • Sweden www.sobi.com
Swedish Orphan Biovitrum AB (Sobi) — Merger or Acquisition (September 2019) on 6ix